ArticleBMC pediatrics2025
Prognosis of nasopharyngeal carcinoma in children and adolescents: a population-based analysis.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- Pediatric Nasopharyngeal Carcinoma: Survival Outcomes and Late Toxicity Burden from a 20-Year Single-Center Experience.Children (Basel, Switzerland) · 2026Article
- Quality and dissemination of nasopharyngeal cancer health information on TikTok and Bilibili: Cross-sectional study.Medicine · 2026Article
- Pediatric Nasopharyngeal Carcinoma (NPC).Current oncology reports · 2026Review
- Prediction of local recurrence in cohorts of head and neck cancer patients after intensity-modulated radiation therapy based on CT radiomics: A double-center observation study.Translational oncology · 2026Article
- Case Report: Pediatric nasopharyngeal carcinoma masquerading as benign lymphadenopathy: diagnostic pitfalls in two cases.Frontiers in pediatrics · 2026Article
- Global, regional, and national burden of pediatric nasopharyngeal carcinoma (1990-2021) and projections of future disease burden trends.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study is to use a population-based cohort to examine the clinicopathological features and survival outcomes of nasopharyngeal cancer (NPC) in children and adolescents.
methodsDemographic and clinicopathological variables of pediatric patients diagnosed with NPC were extracted from the Surveillance, Epidemiology, and End Results database (2000-2018). The survival rates were calculated using Kaplan-Meier analysis. Univariate survival analysis used the log-rank test, whereas multivariate analysis used Cox proportional-hazards regression to find factors impacting overall survival (OS).
resultsA total of 233 pediatric patients were analyzed, with a median age at diagnosis of 16 years (range: 7-19 years). The cancers primarily affected males (70.0%). In terms of grade, 8 (3.5%) patients were well and moderately differentiated, 31 (13.3%) patients were poorly differentiated, and 134 (57.5%) patients were undifferentiated. TNM stage and radiotherapy were significant independent predictors of overall survival. The risk of death was higher for M1 stage (hazard ratio (HR) 20.1, 95% confidence interval (CI), 8.0-50.5; P < 0.001) as compared to M0 stage. Furthermore, multivariate analysis revealed a significant survival advantage for radiotherapy treatment (HR 0.24, 95% CI, 0.09-0.68; P = 0.007).
conclusionNPC in children is rare and should be studied independently. This study found that TNM stage and radiotherapy were the most significant survival predictors, emphasizing the importance of these parameters in the prediction and treatment of pediatric NPC. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.